openPR Logo
Press release

Merkel Cell Carcinoma Pipeline Analysis by Therapeutics, Clinical Trials & Results, Collaboration

Merkel Cell Carcinoma Pipeline Analysis by Therapeutics,

Merkel cell carcinoma is a type of skin cancer that develops as painless bumps, due to sun exposure. Bumps can be red-violet coloured or skin coloured and grow rapidly surrounding lymph nodes. The risk factors associated with merkel cell carcinoma are excessive sun exposure, chronic immune suppression, merkel cell polyomavirus, and aging. The main cause of occurrence of merkel cell carcinoma is somatic mutations in DNA. The tumour formed in merkel cell carcinoma, is comprised of small uniform round blue cells that are arranged in the cluster, bands, and cords forms. Millennium Pharmaceuticals, Inc. is in the process of developing MLN0128 as a mTOR protein inhibitor for the treatment of merkel cell carcinoma. Bristol-Myers Squibb Company is in the process of developing ipilimumab as a cytotoxic T-lymphocyte antigen 4 inhibitor for the treatment of merkel cell carcinoma. Some of the companies having the pipeline of merkel cell carcinoma include Millennium Pharmaceuticals, Inc., NantKwest, Inc., Bristol-Myers Squibb Company and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/merkel-cell-carcinoma-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Merkel Cell Carcinoma Pipeline Analysis by Therapeutics, Clinical Trials & Results, Collaboration here

News-ID: 974227 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for Merkel

Global Merkel Cell Carcinoma Treatment Market Insights, Forecast
Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally occurs most often on sun-exposed areas of the skin. The global Merkel Cell Carcinoma Treatment market is
Merkel Cell Carcinoma Treatment Market : Opportunities, Demand and Forecasts, 20 …
Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally occurs most often on sun-exposed areas of the skin. A delicate resistant background likewise expands the danger of
Merkel Cell Carcinoma - Pipeline Review, H1 2017
Market Research Hub includes new market research report "Merkel Cell Carcinoma - Pipeline Review, H1 2017" to its huge collection of research reports. Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts
Merkel, Abe at Odds on How to Improve World Economy
German Chancellor Angela Merkel and Japanese Leader Shinzo Abe differ on how best to boost the worldwide economy ahead of a G7 gathering this month. New York, NY, USA, May 31, 2016 -- While Abe made a trademark pitch for major boost in spending, Merkel said Germany was already doing what is needed, referring to the additional increase in domestic demand brought by the arrival of one million evacuees and transients
IVU’s CEO accompanies German Chancellor Angela Merkel to Vietnam
Berlin software company hopes to promote smoothly operating transport in Vietnam On Tuesday, German Federal Chancellor Angela Merkel began a state visit to Vietnam, accompanied by representatives from 15 medium-sized German companies. The only Berlin company among the delegation is IVU Traffic Technologies AG, represented by its CEO Martin Müller-Elschner. The visitors to Hanoi and Ho Chi Minh City also attended a German-Vietnamese economic forum. Here all the parties hoped
Rotary honors Chancellor Merkel for supporting a polio-free world
(Berlin, GERMANY – 9 May 2008) In recognition of her contributions toward ending polio worldwide, Rotary International today presented Chancellor Angela Merkel with its Polio Eradication Champion Award. The award, presented by Robert Scott, Chair of the Rotary Foundation of Rotary International, and accepted by Minister H. Wieczorek-Zeul on the Chancellor’s behalf, was established in 1995 to recognize governments and world leaders who have made outstanding contributions toward the goal